ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company